Pfizer's stock is trading at its lowest level in 13 years, down significantly due to reduced COVID-19 product sales and ongoing tariff uncertainties. Although investors see potential in its valuation, supported by a high dividend yield and a favorable forward P/E, the pharmaceutical giant faces risks, including the declining sales of key products like the Comirnaty vaccine and Paxlovid. The CEO highlights the importance of dividend sustainability, but challenges in generating adequate free cash flow raise concerns. Despite a strong oncology pipeline, caution is advised for potential investors.
Pfizer's stock has fallen to its lowest level in 13 years as pressure from falling blockbuster drug sales weighs on performance.
Despite a robust oncology pipeline, Pfizer's struggles with free cash flow to maintain a high-priority dividend raise substantial concerns for investors.
Collection
[
|
...
]